Gut microbiota and its metabolites in depression: from pathogenesis to treatment

Liu, Lanxiang; Wang, Haiyang; Chen, Xueyi; Zhang, Yangdong; Zhang, Hanping; Xie, Peng

doi:10.1016/j.ebiom.2023.104527

reviewEBioMedicineMar 22, 2023GOLD OA

Gut microbiota and its metabolites in depression: from pathogenesis to treatment

LLLanxiang Liu HWHaiyang Wang XCXueyi Chen YZYangdong Zhang HZHanping Zhang

The Affiliated Yongchuan Hospital of Chongqing Medical University · Chongqing Medical University · +1 more institution

PubMed

Indexed incrossrefdoajpubmed

Abstract

Major depressive disorder is one of the most disabling mental disorders worldwide. Increasing preclinical and clinical studies have highlighted that compositional and functional (e.g., metabolite) changes in gut microbiota, known as dysbiosis, are associated with the onset and progression of depression via regulating the gut-brain axis. However, the gut microbiota and their metabolites present a double-edged sword in depression. Dysbiosis is involved in the pathogenesis of depression while, at the same time, offering a novel therapeutic target. In this review, we describe the association between dysbiosis and depression, drug-microbiota interactions in antidepressant treatment, and the potential health…

Citation impact

593

total citations

FWCI: 86.49
Percentile: 100%
References: 123

Citations per year

Authors

6

Topics & keywords

Topics

Keywords

Dysbiosis
Gut flora
Synbiotics
Fecal bacteriotherapy
Depression (economics)
Medicine
Gut–brain axis
Antidepressant

UN Sustainable Development Goals

Good health and well-being

No related works found for this paper.